Literature DB >> 33152058

Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia.

Abhishek A Mangaonkar1, Kaaren K Reichard2, Moritz Binder1, Giacomo Coltro3,4, Terra L Lasho1, Ryan M Carr1, April Chiu2, Vivian Negron5, Mehrdad Hefazi1, Theodora Anagnostou6, Michael M Timm7, James W Hiebert1, Jose C Villasboas1, Wilson I Gonsalves1, Naseema Gangat1, Mithun Shah1, Hassan B Alkhateeb1, Aref Al-Kali1, Michelle A Elliott1, Kebede H Begna1, Alexandra P Wolanskyj-Spinner1, Mark R Litzow1, William J Hogan1, Stephen M Ansell1, Animesh Pardanani1, Ayalew Tefferi1, Mrinal M Patnaik1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33152058      PMCID： PMC7656937          DOI： 10.1182/bloodadvances.2020002415

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  25 in total

1.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Authors:  Maria T Pallotta; Ciriana Orabona; Claudia Volpi; Carmine Vacca; Maria L Belladonna; Roberta Bianchi; Giuseppe Servillo; Cinzia Brunacci; Mario Calvitti; Silvio Bicciato; Emilia M C Mazza; Louis Boon; Fabio Grassi; Maria C Fioretti; Francesca Fallarino; Paolo Puccetti; Ursula Grohmann
Journal:  Nat Immunol       Date:  2011-07-31       Impact factor: 25.606

2.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

3.  Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta.

Authors:  D D Taub; K Conlon; A R Lloyd; J J Oppenheim; D J Kelvin
Journal:  Science       Date:  1993-04-16       Impact factor: 47.728

4.  Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.

Authors:  Alexander Kiani; Ivonne Habermann; Knut Schäke; Andreas Neubauer; Lars Rogge; Gerhard Ehninger
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

5.  Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.

Authors:  Eric Grignano; Arsene Mekinian; Thorsten Braun; Eric Liozon; Mohamed Hamidou; Olivier Decaux; Xavier Puéchal; Jean Emmanuel Kahn; Yoland Schoindre; Julien Rossignol; Olivier Lortholary; Bertrand Lioger; Olivier Hermine; Sophie Park; Lionel Ades; François Montestruc; Laure Ricard; Claude Gardin; Pierre Fenaux; Olivier Fain
Journal:  Leuk Res       Date:  2016-06-02       Impact factor: 3.156

Review 6.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2012-10-25       Impact factor: 16.687

Review 7.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

8.  A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection.

Authors:  Alison Crawford; Jill Marie Angelosanto; Kim Lynn Nadwodny; Shawn D Blackburn; E John Wherry
Journal:  PLoS Pathog       Date:  2011-07-21       Impact factor: 6.823

9.  Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission.

Authors:  G Pizzolo; L Trentin; F Vinante; C Agostini; R Zambello; M Masciarelli; C Feruglio; F Dazzi; G Todeschini; M Chilosi
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

10.  Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.

Authors:  Valentina Folgiero; Bianca M Goffredo; Perla Filippini; Riccardo Masetti; Giuseppina Bonanno; Roberta Caruso; Valentina Bertaina; Angela Mastronuzzi; Stefania Gaspari; Marco Zecca; Giovanni F Torelli; Anna M Testi; Andrea Pession; Franco Locatelli; Sergio Rutella
Journal:  Oncotarget       Date:  2014-04-30
View more
  7 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 2.  Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond.

Authors:  Siba El Hussein; Joseph D Khoury; L Jeffrey Medeiros; Sanam Loghavi
Journal:  Curr Hematol Malig Rep       Date:  2021-05-04       Impact factor: 3.952

3.  Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Alexandra Keller; Daniel Ivanov; Barbara Peter; Daniela Berger; Gabriele Stefanzl; Karin Bauer; Katharina Slavnitsch; Georg Greiner; Karoline V Gleixner; Wolfgang R Sperr; Michael Willmann; Heinz Sill; Peter Bettelheim; Klaus Geissler; Michael Deininger; Thomas Rülicke; Peter Valent
Journal:  Leukemia       Date:  2021-03-30       Impact factor: 12.883

Review 4.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

Review 5.  Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding.

Authors:  Abhishek A Mangaonkar; Aaron J Tande; Delamo I Bekele
Journal:  Curr Hematol Malig Rep       Date:  2021-04-20       Impact factor: 3.952

Review 6.  Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms.

Authors:  Xavier Roussel; Francine Garnache Ottou; Florian Renosi
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

Review 7.  Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Authors:  Livingstone Fultang; Luciana Gneo; Carmela De Santo; Francis J Mussai
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.